First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Overview

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.

Full Title of Study: “First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 28, 2024

Interventions

  • Drug: RGT-419B
    • oral capsules
  • Drug: RGT-419B in combination with hormonal therapy
    • RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)

Arms, Groups and Cohorts

  • Experimental: Arm A
    • RGT-419B given alone as monotherapy
  • Experimental: Arm B
    • RGT-419B in combination with Hormonal Therapy

Clinical Trial Outcome Measures

Primary Measures

  • Safety & Tolerability – Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in singlet and doublet therapy
    • Time Frame: 4 weeks (1 cycle)
    • Number of subjects who have a confirmed DLT at each cohort dose level in singlet and doublet study arms during the first 28-day cycle of RGT-419B treatment.

Secondary Measures

  • Safety & Tolerability – Incidence, Severity, and Causality of all Treatment Emergent Adverse Events (TEAEs)
    • Time Frame: through study completion, an average of 1 year
    • Incidence, severity, and causality of all TEAEs will be assessed for all patient participating from Day 1 dosing through end of study.
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Cmax
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Area Under Concentration-Time Curve (AUC0-t)
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Area Under Concentration-Time Curve to Infinity (AUC0-inf)
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Plasma Decay Half-Life (t 1/2)
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Time to Reach Maximum Observed Plasma Concentration (Tmax)
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Accumulation rate after multiple doses
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Day 1 and steady-state PK assessment of RGT-419B and major metabolites – Cumulative urinary excretion
    • Time Frame: through study completion, an average of 1 year
    • Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification
  • Tumor Response assessed by Investigator according to RECIST v1.1
    • Time Frame: through study completion, an average of 1 year
    • Tumor response measured by radiologic imaging techniques at baseline and throughout the study
  • QTc Interval – Changes in corrected QT interval
    • Time Frame: through study completion, an average of 1 year
    • Number of subjects with a clinically significant increase from baseline in corrected QT (QTc) interval on repeated ECGs during RGT-419B monotherapy.

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female >/= 18 years old 2. ECOG Performance Status 0 to 1 3. HR+, HER2- tumor by most recent biopsy with measurable disease 4. Have had no more than 1 prior line of cytotoxic chemotherapy in the ABC setting AND no serious/severe toxicity to a prior CKD4/6i AND no known contraindication to receiving RT-419B AND have had all acute/residual toxic effects of any prior therapy 5. In the ABC setting, eligible subjects must have failed to respond to or progressed after <3 lines of prior CDK4/6i therapy and unlimited lines of prior HT and have had no more than 1 prior line of chemotherapy. Eligible subjects must have received and progressed on any combination of HTs including any approved AI, SERD, or SERM, and/or any approved CDK4/6i in any order. (5a) For subjects in Arm B, at least one line of prior therapy must have included a locally approved HT which was well tolerated and which the subject is willing to receive again (5b) Subjects with tumors harboring a PIK3CA mutation will be allowed to enroll, and treatment with a PI3Ki in combination with HT will be allowed as a prior line of therapy. Surgical excision of tumor tissue accompanied by chemotherapy or targeted therapy is also counted as 1 line of prior treatment. Exclusion Criteria:

1. Presence of visceral metastases with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and/or rapid progression of disease 2. Pregnant or planning to become pregnant 3. Prior irradiation to >25% of the bone marrow and/or inadequate bone marrow function or evidence of clinically significant end-organ damage 4. Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14 days prior to Cycle 1, Day 1 5. Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol 6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Regor Pharmaceuticals Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Regor Central Office, 617-315-9070, rgt-419b_01-101@regor.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.